At ID Week 2025, ViiV Healthcare presented new real-world evidence demonstrating that Cabenuva (cabotegravir + rilpivirine long-acting, or CAB+RPV LA) significantly improves treatment adherence and viral suppression among people with HIV...
At ID Week 2025, ViiV Healthcare presented new real-world evidence demonstrating that Cabenuva (cabotegravir + rilpivirine long-acting, or CAB+RPV LA) significantly improves treatment adherence and viral suppression among people with HIV...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
At a recent AMCP conference, health care leaders Maria Lopes, MD, and Steve Cohen, MD, highlighted the persistent and unique challenges of HIV management in the US, emphasizing that despite medical advancements, HIV remains classified as an...
Access to long-acting injectable antiretroviral therapy (LAI-ART) remains limited across the US despite its potential to improve adherence and outcomes for people with HIV, particularly those facing challenges with daily oral therapy.
Access to long-acting injectable antiretroviral therapy (LAI-ART) remains limited across the US despite its potential to improve adherence and outcomes for people with HIV, particularly those facing challenges with daily oral therapy.
A new observational study examining commercially insured adults in the United States has revealed the substantial long-term economic burden associated with HIV, showing that lifetime costs for people with HIV (PWH) exceed those for...
A new observational study examining commercially insured adults in the United States has revealed the substantial long-term economic burden associated with HIV, showing that lifetime costs for people with HIV (PWH) exceed those for...
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
Addressing stigma associated with pre-exposure prophylaxis (PrEP) is crucial for improving its uptake and adherence among eligible populations, according to study results published in Sexes.
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
The Centers for Disease Control and Prevention (CDC) has awarded $400 million in funding to boost HIV prevention and surveillance efforts across the United States, aiming to accelerate progress in reducing new infections and improving health...
Despite recommendations for routine prenatal care, pregnant women living with HIV (PLHIV) are receiving routine vaccinations at alarmingly low rates, according to a study published in JAMA Network Open.
Despite recommendations for routine prenatal care, pregnant women living with HIV (PLHIV) are receiving routine vaccinations at alarmingly low rates, according to a study published in JAMA Network Open.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
As HIV rates continue to rise among Latino gay and bisexual men, health policy advocates stress the need for more federal assistance for HIV treatment and prevention in this community.
A computational method has been developed to identify HIV-1 broadly neutralizing antibodies (bNAbs) from non-selected immune repertoires, researchers reported in the journal Nature Communications.
A computational method has been developed to identify HIV-1 broadly neutralizing antibodies (bNAbs) from non-selected immune repertoires, researchers reported in the journal Nature Communications.
Johnson & Johnson aims to expand use of its HIV-1 therapy, Prezcobix, for younger patients in the US, potentially paving the way for improved treatment options for pediatric patients with the virus.
Johnson & Johnson aims to expand use of its HIV-1 therapy, Prezcobix, for younger patients in the US, potentially paving the way for improved treatment options for pediatric patients with the virus.
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
